FDA budget
This article was originally published in The Gray Sheet
Executive Summary
The House Appropriations committee passes the $18.4 bil. "Agriculture, Rural Development, FDA, and Related Agencies Appropriations" bill for FY 2007 on May 9. For the second year in a row, the legislation contains an amendment forwarded by Congressman Maurice Hinchey (D-N.Y.) that would prohibit scientists and doctors with conflicts of interest from serving on FDA advisory panels. In October 2005, Congress approved a reconciled version of the FY 2006 spending bill with a watered-down version of Hinchey's conflict-of-interest provision (1"The Gray Sheet" Oct. 31, 2005, In Brief). The FY 2007 bill, which allots $229 mil. for the Center for Devices and Radiological Health, will now be taken up by the full House (2"The Gray Sheet" Feb. 13, 2006, p. 6)...
You may also be interested in...
FDA Budget Request Proposes New User Fee For Facility Reinspections
FDA is proposing a new mandatory user fee that would require device and drug manufacturers to pay for reinspections of manufacturing facilities cited for violations
FDA panel conflicts of interest
Reconciled FY 2006 FDA appropriations bill passes the House Oct. 28 with a "very watered-down" version of an advisory committee conflict-of-interest (CoI) provision, according to Rep. Maurice Hinchey (D-N.Y.), who succeeded in adding a CoI amendment to the original House bill in June. The final language requires that panel member conflicts of interest and waivers for conflicts be posted on FDA's website at least 15 days prior to a meeting or as soon as possible if the conflict is identified closer to the meeting date. Hinchey's amendment would have prohibited FDA from granting CoI waivers (1"The Gray Sheet" June 13, 2005, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.